The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | COSMOS: key updates for MOR208 plus venetoclax for R/R CLL
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, discusses the results of the COSMOS trial (NCT02639910), investigating anti-CD19 MOR208 in combination with venetoclax in chronic lymphocytic leukemia (CLL) patients who discontinued BTK inhibitor therapy. This revealed encouraging activity, with acceptable safety and tolerability.
